BMS Gains Second Indication For Krazati – One More Than Amgen’s Lumakras

CRC Added To NSCLC, Both Second-Line Or Later

Bristol Myers Squibb won US FDA approval in colorectal cancer for the KRAS G12C inhibitor from its $4.8bn Mirati buy, but Amgen’s first-to-market product still has a big commercial lead.

Approach to colon research using modern technologies
Krazati is the first KRAS G12C inhibitor approved in colorectal cancer • Source: Shutterstock

More from New Products

More from Scrip